Frontiers in Immunology (Feb 2025)

The clinical significance of T-cell regulation in hypertension treatment

  • Miaoxin Fu,
  • Mingzhu Lv,
  • Jinyue Guo,
  • Aihua Mei,
  • Hang Qian,
  • Handong Yang,
  • Wenwen Wu,
  • Wenwen Wu,
  • Zhixin Liu,
  • Jixin Zhong,
  • Ying Wei,
  • Xinwen Min,
  • Haiyan Wu,
  • Jun Chen,
  • Jun Chen

DOI
https://doi.org/10.3389/fimmu.2025.1550206
Journal volume & issue
Vol. 16

Abstract

Read online

Hypertension, a globally prevalent condition, is closely associated with T cell-mediated inflammatory responses. Studies have shown that T cells, by secreting pro-inflammatory cytokines such as interferon-gamma (IFN-γ), Interleukin-17 (IL-17), and Tumor necrosis factor-alpha (TNF-α), directly lead to vascular dysfunction and elevated blood pressure. The activation of Th1 and Th17 cell subsets, along with the dysfunction of regulatory T cells (Tregs), is a critical mechanism in the onset and progression of hypertension. This review explores the role of T cells in the pathophysiology of hypertension and discusses potential therapeutic strategies targeting T cell regulation, such as immunotherapy and gene-editing technologies. These emerging treatments hold promise for providing personalized therapeutic options for hypertensive patients, reducing inflammatory complications, and improving treatment outcomes.

Keywords